Tonix Pharmaceuticals Holding (LTS:0A4T) ROCE % : -68.20% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Tonix Pharmaceuticals Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tonix Pharmaceuticals Holding's annualized ROCE % for the quarter that ended in Mar. 2024 was -68.20%.

Tonix Pharmaceuticals Holding ROCE % Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding ROCE % Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-174.26

-103.31

-60.03

-52.54

-69.01

Tonix Pharmaceuticals Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-72.61	-75.50	-85.67	-85.03	-68.20

Tonix Pharmaceuticals Holding ROCE % Calculation

Tonix Pharmaceuticals Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-118.38	/	( ( (225.69 - 18.18)	+	(154.457 - 18.884) )	/ 2 )
	=	-118.38	/	( (207.51	+	135.573)	/ 2 )
	=	-118.38	/	171.5415
	=	-69.01 %

Tonix Pharmaceuticals Holding's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-85.404	/	( ( (154.457 - 18.884)	+	(135.343 - 20.479) )	/ 2 )
	=	-85.404	/	( ( 135.573	+	114.864 )	/ 2 )
	=	-85.404	/	125.2185
	=	-68.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Tonix Pharmaceuticals Holding (LTS:0A4T) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tonix Pharmaceuticals Holding ROCE % Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (LTS:0A4T) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (LTS:0A4T) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TNXP:USA

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (LTS:0A4T) Headlines

No Headlines